860692-66-6

Upstream product

• 65-49-6 4-Aminosalicylic acid 
• 4136-97-4 methyl 4-aminosalicylate 
• 109-65-9 1-bromo-butane 
• 4093-28-1 methyl 4-acetamido-2-hydroxybenzoate 

Downstream Products

• 61566-62-9 4-amino-2-butoxy-benzoic acid 
• 119-29-9 benoxinate 
• 860695-82-5 2-butoxy-4-isopropylamino-benzoic acid 
• 695184-67-9 2-butoxy-4-butylamino-benzoic acid 
• 78329-83-6 2-butoxy-4-butylamino-benzoic acid-(2-dimethylamino-ethyl ester) 
• 1028127-13-0 methyl 4-acetylamino-2-butoxy-5-nitrobenzoate 

Relevant academic research and scientific papers

Methyl 4-acetamido-2-butoxybenzoate derivatives as well as preparation method and application thereof

The invention relates to methyl 4-acetamido-2-butoxybenzoate derivatives as well as a preparation method and application thereof, and belongs to the field of medicinal chemistry. The structural formula of the methyl 4-acetamido-2-butoxybenzoate derivatives is shown in the specification, wherein R1 is alkyl, substituted phenyl, heteroaromatic ring group or substituted styryl; and R2 is fatty aminoor benzylamino. The preparation method is simple and high in yield. Most compounds provided by the invention have good influenza virus neuraminidase inhibition activity.

Design, synthesis, inhibitory activity, and SAR studies of hydrophobic p-aminosalicylic acid derivatives as neuraminidase inhibitors

A series of hydrophobic p-aminosalicylic acid derivatives containing a lipophilic side chain at C-2 and an amino or guanidine at C-5 were synthesized and evaluated for their ability to inhibit neuraminidase (NA) of influenza A virus (H3N2). All compounds were synthesized in good yields starting from commercially available p-aminosalicylic acid (PAS) using a suitable synthetic strategy. These compounds showed potent inhibitory activity against influenza A NA. Within this series, six compounds, 11, 12, 13e, 16e, 17c, and 18e, have the good potency (IC50 = 0.032-0.049 μM), which are compared to Oseltamivir (IC50 = 0.021 μM) and could be used as lead compounds in the future.